

# Efficacy and Safety of Abrocitinib in Asian Adolescents with Atopic Dermatitis: A Review of Real-World Data in Singapore

Thurston Yan Jia Heng<sup>1</sup>, Elis Lee Yuexian<sup>1,2</sup>, Valerie PY Ho<sup>1,2</sup>

<sup>1</sup>Department of Paediatric Medicine, KK Women's and Children's Hospital, Singapore

<sup>2</sup>Department of Dermatology, KK Women's and Children's Hospital, Singapore

**Learning Objective:** To assess the efficacy and safety of Abrocitinib for adolescents in Singapore with atopic dermatitis

**Takeaway Message:** Abrocitinib is an effective and safe oral medication for Asian adolescents with atopic dermatitis including non responders to other second line agents

For clarifications, kindly contact us at [thurston.heng@mohh.com.sg](mailto:thurston.heng@mohh.com.sg) or [valerie.ho.p.y@singhealth.com.sg](mailto:valerie.ho.p.y@singhealth.com.sg)

The authors have no conflict of interest to declare

KKH Celebrates




Shaping the future of  
Women and Children

# Background

Atopic dermatitis (AD) is a common chronic condition in the paediatric population. Oral Janus kinase 1 inhibitors are increasingly used to optimise AD control.

However, real world data in the Asian paediatric population is limited.



Garcia-Melendo C, et al. Janus Kinase Inhibitors in Dermatology: Part 1

# Methodology

**22 children** aged 12 years and older were started on Abrocitinib for moderate-severe AD from May 2024

Exclusion criteria: **2 patients** have yet to undergo **1 month** review

Ambispective cohort study

Data collected at **baseline, 1 month, 3-4 months, 6-8 months** after commencement of Abrocitinib including


- EASI scores and other results
- Patient reported outcomes (itch, sleep, mood, etc)
- Patient reported side effects
- Laboratory results

**2** discontinued Abrocitinib due to side effects/suboptimal disease control

**18** are still on Abrocitinib with regular reviews

# Demographics

<b>Total, n</b>	20
<b>Age, years (mean <math>\pm</math> SD)</b>	14.9 (1.86)
<b>Weight, kg (mean <math>\pm</math> SD)</b>	57.98 (14.58)
<b>Prior 2<sup>nd</sup> line treatment, n (%)</b>	11 (55)



KK Women's and  
Children's Hospital  
SingHealth


KKH Celebrates



Shaping the future of  
Women and Children

# Demographics

## PRIOR SECOND LINE TREATMENT



\*Methotrexate, Ciclosporin

## Reasons for Starting Abrocitinib

Concerns regarding side effect profile of 2<sup>nd</sup> line treatment

35%

Poor response to prior 2<sup>nd</sup> line treatment

30%

Fear of injections

20%

Financial concerns

15%

Complications of previous systemic treatment

10%




KK Women's and  
Children's Hospital  
SingHealth

KKH Celebrates


165  
Years

Shaping the future of  
Women and Children

# Demographics



# Results



Duration	Mean EASI Score ( $\pm$ SD)	Median EASI Score
Initial	20.54 (5.96)	18.4
1 month	10.83 (6.98)	10.3
3-4 months	11.39 (6.92)	10.9
6-8 months	9.49 (6.43)	9.9

35% felt their itch was better controlled  
20% felt their sleep improved

# Case



EASI 21.6 (17 May 2024)

17-year-old boy with  
atopic dermatitis and  
prurigo nodules  
following use of  
Abrocitinib 200mg  
with improvement in  
EASI by 36.1%




EASI 13.8 (11 June 2024)





EASI 21.6 (17 May 2024)



EASI 13.8 (11 June 2024)



KK Women's and  
Children's Hospital  
SingHealth

KKH Celebrates

165  
Years

Shaping the future of  
Women and Children

# Results

## No reported major adverse outcomes

### Minor adverse outcomes

- **5** developed **minor side effects** including upper respiratory tract infection, acne, headache, nausea
- **3** patients developed **raised low density lipoprotein (LDL)**
- **1** patient had **raised alanine transaminase (ALT)**
- **None** had anemia, leukopenia or thrombocytopenia
- **None** had electrolyte derangements



KK Women's and  
Children's Hospital  
SingHealth

KKH Celebrates



Shaping the future of  
Women and Children

# Summary

Based on our cohort of patients, Abrocitinib is an effective and safe oral medication for Asian adolescents with AD, including non-responders to other second line agents.

# References

1. Garcia-Melendo C, Cubiró X, Puig L. Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata. *Actas Dermo-Sifiliográficas* (English Edition). 2021;112(6):503-515. doi:<https://doi.org/10.1016/j.adengl.2021.03.012>
2. Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatol*. 2020;156(8):863-873. doi:10.1001/jamadermatol.2020.1406
3. Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2020;396(10246):255-266. doi:10.1016/S0140-6736(20)30732-7
4. Liang J, Ye H, Wang J, et al. Effectiveness and safety of age-based dosing of abrocitinib in children and adolescents with moderate to severe atopic dermatitis: A two-center, prospective real-world study in China. *Medicine* (Baltimore). 2025;104(16):e42231. doi:10.1097/MD.00000000000042231